Monte Rosa Therapeutics (GLUE) Liabilities and Shareholders Equity (2020 - 2026)

Monte Rosa Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $736.4 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 87.29% year-over-year to $736.4 million; the TTM figure through Mar 2026 stood at $2.0 billion (up 34.43% YoY), while the FY2025 annual figure was $448.7 million, up 2.26% from the prior year.
• Liabilities and Shareholders Equity was $736.4 million for Q1 2026 at Monte Rosa Therapeutics, up from $448.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $736.4 million in Q1 2026 to a low of $252.1 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $371.6 million across 5 years, with a median of $346.0 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity retreated 29.5% in 2023, then soared 87.29% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $342.4 million in 2022, then declined by 11.28% to $303.8 million in 2023, then jumped by 44.44% to $438.7 million in 2024, then grew by 2.26% to $448.7 million in 2025, then jumped by 64.14% to $736.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $736.4 million (Q1 2026), $448.7 million (Q4 2025), and $459.8 million (Q3 2025), per Business Quant data.